Closed · RFA-FD-14-011 · CFDA 93.103 · Discretionary
Pharmacometric Modeling and Simulation for Generic Drugs Evaluation
Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.
- $150K-$250K
- Award range
- Closed
- Status
- June 2, 2014
- Close date
- 5
- Expected awards
The verdict
Pharmacometric Modeling and Simulation for Generic Drugs Evaluation is a closed discretionary listing from Food and Drug Administration that offered $150,000 -- $250,000 across 5 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.
- $150K-$250K
- award range
- Closed
- application status
- 5
- expected awards
- 93.103
- CFDA program
Archived opportunity record
Pharmacometric Modeling and Simulation for Ge… is closed (last close June 2, 2014). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed June 2, 2014
Est. Total Funding
$1,250,000
Expected Awards
5
Instrument
Cooperative Agreement
Description
Computational modeling and simulation is one of the priority areas of Fiscal Year 14 GDUFA (Generic Drug User Fee Act) Regulatory Research program. It is essential to developing a modern ANDA (Abbreviated New Drug Application) review process that fully utilizes available computational and analytical tools. The focus of this FOA/RFA is to utilize pharmacometric modeling and simulation and develop quantitative methodology for generic drugs evaluation in several areas.Objectives:The objectives of this project are to develop quantitative models for generic drugs evaluation in the following areas:1. Population pharmacokinetic and pharmacodynamic, dose-efficacy, and dose-toxicity modeling and simulation for narrow therapeutic index (NTI) drugs. The goal is to develop models and modeling approaches that will help FDA classify drugs as having a narrow therapeutic index and identify those products that have a clinical use profile that requires tighter control of product quality and equivalence attributes.2. Pharmacometric modeling and simulation for generic drug substitutability evaluation and post marketing risk assessment. The goal is to develop pharmacometic approaches (including clinical trial simulation and clinical use/substitution simulation) that will aid OGD in the evaluation of post-market risk and the interpretation of post-market adverse event reports or product substitution complaints.3. Pharmacometric modeling and simulation for partial AUC (area under the concentration vs. time curve) as bioequivalence criteria. The goal is to develop modeling and simulation tools that will aid FDA in identifying which generic drug products require greater degrees of pharmacokinetic profile similarity in order to assure therapeutic equivalence.Detailed Description:Applicants who wish to apply for more than one subtopic should submit separate proposals for each subtopic as listed below: Subtopic 1: Population pharmacokinetic and pharmacodynamic, dose-efficacy, and dose-toxicity modeling and simulation for narrow therapeutic index (NTI) drugs.The objective of this subtopic is to develop population pharmacokinetic and pharmacodynamic, dose-efficacy, and dose-toxicity modeling and simulation for narrow therapeutic index (NTI) drugs. The quantitative model will be used to (1) define whether the drug candidate is belonged to NTI drugs, and (2) evaluate bioequivalence criteria for NTI drugs.Subtopic 2: Pharmacometric modeling and simulation for generic drug substitutability evaluation and post marketing risk assessment.The objective of this subtopic is to develop pharmacometric modeling and simulation methodology to evaluate generic substitutability to address concerns about generic drug substitutability and for post marketing risk assessment. The suggested model drug products include but are not limited to antiepileptic drugs, attention deficit hyperactivity disorder drugs, and antidepressants.Subtopic 3: Pharmacometric modeling and simulation for partial AUCs (area under the concentration vs. time curve) as bioequivalence criteria.The objective of this subtopic is to develop pharmacometric modeling and simulation methodology to evaluate partial AUCs as bioequivalence criteria. Some examples of specific questions to answer are (1) whether partial AUCs are needed for these drug products, (2) what are the appropriate partial AUCs for evaluation of bioequivalence.
Wide-open applicant board · 15 Grants.gov doors
Pharmacometric Modeling and Simulation for Ge… prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Science and Technology / R&D (HL;ST). 120 other Food and Drug Administration listings share this eligibility-code string (25% of 482).
- Code 00
- State governments
- Code 01
- County governments
- Code 02
- City or township governments
- Code 04
- Special district governments
- Code 05
- Independent school districts
- Code 06
- Public / state-controlled institutions of higher education
- Code 07
- Federally recognized tribal governments
- Code 08
- Public / Indian housing authorities
- Code 11
- Native American tribal organizations (other than Federally recognized tribal governments)
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 13
- Nonprofits without 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 22
- For-profit organizations other than small businesses
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Food and Drug Administration Research
U.S. Department of Health and Human Services
Agency Contact
Gladys Melendez-Bohler Grants Management Specialist Phone 301-827-7175
More from Food and Drug Administration
Federal and University Partnership to Improve the Safety of Seafood from the Gulf of America
Research, Education, and Outreach on Botanical Natural Products
Cooperative Agreement to Support Shellfish Safety Assistance Project
Education and Outreach to Tribal Producers through the Tribal Food Safety Alliance
Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional
What to do next
Pharmacometric Modeling and Simulation for Ge… is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
- Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
- Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |